SEC Company Response from Anixa Biosciences Inc (ANIX) (CIK 0000715446) (ANIX) — Sep 15, 2022

Anixa Biosciences Inc (ANIX) (CIK 0000715446)
Date: Sept. 15, 2022 · CIK: 0000715446 · Accession: 0001493152-22-025981

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-267369

Date

Sept. 15, 2022

Author

Dr. Amit Kumar

Form

CORRESP

Company

Anixa Biosciences Inc (ANIX) (CIK 0000715446)

Letter

VIA EDGAR Division of Corporation Finance Office of Life Sciences Re: Anixa Biosciences, Inc. Registration Statement on Form S-3 Filed September 9, 2022, as amended File No. 333-267369

Dear Mr. Howes:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Anixa Biosciences, Inc., hereby requests acceleration of effectiveness of the above referenced Registration Statement so that it will become effective at 4:30 p.m. EST on Monday, September 19, 2022, or as soon as thereafter practicable.

Very
truly yours,
/s/
Dr. Amit Kumar

Show Raw Text

CORRESP
1
filename1.htm

ANIXA
BIOSCIENCES, INC.

3150
Almaden Expressway, Suite 250

San
Jose, CA 95118

September
15, 2022

VIA
EDGAR

U.S.
Securities and Exchange Commission

Division
of Corporation Finance

Office
of Life Sciences

100
F Street, N.E.

Washington,
DC 20549

Attn:
Tyler Howes

    Re:
    Anixa
    Biosciences, Inc.

    Registration
    Statement on Form S-3

    Filed
    September 9, 2022, as amended

    File
    No. 333-267369

Dear
Mr. Howes:

Pursuant
to Rule 461 under the Securities Act of 1933, as amended, Anixa Biosciences, Inc., hereby requests acceleration of effectiveness of the
above referenced Registration Statement so that it will become effective at 4:30 p.m. EST on Monday, September 19, 2022, or as soon as
thereafter practicable.

    Very
    truly yours,

    /s/
    Dr. Amit Kumar

    Dr.
    Amit Kumar

    Chairman and Chief Executive Officer

    cc:
    Ellenoff
    Grossman & Schole LLP

SecProbe.io